MONTAIR LC TABLET 15'S

Montair LC Tablet 15's is a combination medicine used to treat symptoms of allergy such as runny nose, stuffy nose, sneezing, watery eyes, and itching.

Montair LC Tablet 15's contains two active ingredients: Montelukast and Levocetirizine.

Montair LC Tablet 15's is used to treat allergy symptoms such as runny nose, stuffy nose, sneezing, watery eyes, and itching. It may also be used to treat asthma.

Common side effects of Montair LC Tablet 15's include headache, fatigue, dry mouth, and drowsiness.

Montair LC Tablet 15's can be taken with or without food.

Montair LC Tablet 15's should be stored at room temperature, away from heat and moisture.

The safety and effectiveness of Montair LC Tablet 15's have not been established in children. Please consult a doctor before use.

There is limited information available about the use of Montair LC Tablet 15's during pregnancy. Please consult a doctor before use.

It is not known whether Montair LC Tablet 15's is excreted in breast milk. Please consult a doctor before use.

Symptoms of an overdose of Montair LC Tablet 15's may include drowsiness, agitation, and confusion.

If you miss a dose of Montair LC Tablet 15's, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose.

Drinking alcohol while taking Montair LC Tablet 15's can increase side effects such as drowsiness. Therefore, it is advisable to avoid it.

Montair LC Tablet 15's can interact with other medications. Tell your doctor about all the medications you are taking to avoid any potential interactions.

Yes, Montair LC Tablet 15's can cause drowsiness. Avoid driving or operating machinery if you experience drowsiness after taking this medication.

While taking Montair LC Tablet 15's, you should avoid drinking alcohol and activities requiring mental alertness, such as driving or operating machinery, as the medicine can cause drowsiness.

Montair LC is generally prescribed for the management of allergic conditions such as allergic rhinitis (including seasonal and perennial forms) and for relief of symptoms like sneezing, runny or blocked nose, nasal itching, and watery eyes. Because it contains montelukast, it may also be used as an add-on therapy in patients with asthma where allergy is a significant trigger, to help reduce inflammation and improve symptom control. It is not intended to treat acute asthma attacks.

Montair LC combines two active components with complementary mechanisms. Montelukast blocks leukotriene receptors (CysLT1) in the airways and nasal mucosa, reducing leukotriene-mediated bronchoconstriction, mucus secretion, and inflammation. Levocetirizine selectively blocks peripheral H1 histamine receptors, thereby reducing histamine-induced symptoms such as sneezing, itching, and rhinorrhea. Together, these actions help control both upper airway allergic symptoms and, when indicated, contribute to better asthma control as part of a broader treatment plan.

No. Montair LC is not a rescue medication and should not be used to treat an acute asthma attack or sudden worsening of breathing. Montelukast acts as a controller medicine and has no role in rapid bronchodilation. For acute attacks, fast-acting inhaled bronchodilators, such as short-acting beta-agonists, are typically recommended according to a physician’s instructions. Patients should follow their personalized asthma action plan and seek urgent medical care if symptoms do not improve or worsen.

Commonly reported side effects of Montair LC include headache, abdominal pain, dry mouth, fatigue, and drowsiness or somnolence, particularly due to the antihistamine component levocetirizine. Some patients may experience dizziness, nausea, or diarrhea. Most side effects are mild and transient, but if they persist, become bothersome, or appear to worsen, medical advice should be sought. Any unusual symptoms, especially mood or behavior changes, should be reported promptly.

Yes. Montelukast has been associated, in rare cases, with neuropsychiatric events such as agitation, aggression, anxiety, abnormal dreams, insomnia, depression, hallucinations, and suicidal thoughts or behavior. Although these events are uncommon, they can be serious. If a patient or caregiver notices new or worsening mood changes, behavioral disturbances, or suicidal ideation, the medicine should not be stopped abruptly without medical advice, but urgent consultation with a healthcare professional is essential to reassess therapy. Severe allergic reactions to any component are also possible but rare.

Yes, Montair LC can cause drowsiness or reduced alertness in some individuals, mainly due to levocetirizine, even though it is a second-generation antihistamine with relatively lower sedative potential than older agents. The degree of drowsiness varies between individuals. Patients should observe how they respond to the medicine before driving, operating machinery, or performing tasks that require full mental alertness. Concomitant use of alcohol or other central nervous system depressants can enhance sedative effects and should generally be avoided unless specifically advised by a doctor.

The safety of Montair LC during pregnancy has not been fully established in controlled human studies. Montelukast and levocetirizine have limited human pregnancy data, and animal studies do not always predict human response. Therefore, Montair LC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as assessed by a qualified healthcare professional. Pregnant women or those planning to conceive should inform their doctor before starting or continuing Montair LC so that alternative options or the necessity of therapy can be carefully evaluated.

Both montelukast and levocetirizine may pass into breast milk to some extent. The clinical significance of this exposure in breastfed infants is not fully defined. Montair LC should therefore be used with caution in breastfeeding women, and only when the expected benefit to the mother outweighs any potential risk to the infant. A healthcare professional may consider alternative treatments with better-established safety profiles in lactation or may advise close monitoring of the infant for signs of excessive sleepiness, irritability, or feeding difficulties.

Concomitant use of Montair LC with alcohol is generally not recommended. Alcohol can potentiate the sedative effects of levocetirizine, leading to increased drowsiness, dizziness, and impaired concentration or coordination. This may increase the risk of accidents, particularly when driving or operating machinery. Patients should be advised to avoid or minimize alcohol consumption while taking Montair LC and to discuss any regular alcohol intake with their healthcare provider.

Patients with pre-existing liver or kidney impairment should use Montair LC only under close medical supervision. Both montelukast and levocetirizine undergo hepatic and renal handling to varying degrees, and altered pharmacokinetics may increase the risk of adverse effects. The prescribing physician may decide to adjust the dose, extend dosing intervals, or choose an alternative therapy depending on the severity of hepatic or renal dysfunction and the overall clinical context. Regular monitoring of liver function tests or renal parameters may be advised in selected patients.

Montair LC is available in different strengths and formulations, and pediatric use depends on the child’s age, weight, diagnosis, and local regulatory approvals. In many settings, montelukast and levocetirizine are used in children for allergic rhinitis and asthma-related indications, but the exact dose and formulation must be determined by a pediatrician. Caregivers should never give Montair LC intended for adults to children without explicit medical instruction. Chewable tablets or syrups of individual components may be preferred in younger age groups, and long-term use requires periodic clinical review.